title: Rhabdomyolysis in a Healthy Peripheral Blood Stem Cell Donor following Mobilization with Filgrastim.
abstract: BACKGROUND: Although granulocyte colony stimulating factor (G-CSF) mobilization is generally well tolerated by healthy donors, there is also a wide spectrum of adverse events associated with it. Among these events, rhabdomyolysis in peripheral blood stem cell (PBSC) donors is very rare. In this paper, we present a first case of rhabdomyolysis after administration of filgrastim for PBSC mobilization. CASE REPORT: A 6-year-old donor received 10 mug/kg/day filgrastim subcutaneously for 5 days. On the 3rd day of filgrastim, the donor complained of bone pain; a single dose of paracetamol (250 mg) was given to relieve pain. On the 4th day, she complained of bone pain, myalgia, and vomiting. On laboratory analysis, serum creatine phosphokinase was 1,095 U/l (40-226 U/l), LDH 312 U/l (100-190 U/l), aspartate aminotransferase 85 U/l (0-40 U/l), potassium 3.3 mmol/l (3.6-5.1 mmol/l). Urine myoglobin was 110 ng/ml (<5 ng/ml). Rhabdomyolysis was suspected on clinical and laboratory findings. Clinical manifestations regressed and the laboratory results returned to normal within three days after intravenously forced diuresis and potassium replacement. Stem cells were successfully harvested from peripheral blood on the 5th day of G-CSF therapy. CONCLUSION: Rhabdomyolysis is a rare but important adverse effect of G-CSF. Allogeneic PBSC donors should be closely monitored with regard to rhabdomyolysis after G-CSF administration in the mobilization setting.
authors.affiliation: Department of Hematology, Pamukkale Medical School, Denizli, Kayseri, Turkey.
authors.forename: Sibel
authors.initials: S
authors.lastname: Hacioglu
authors.forename: Fevzi
authors.initials: F
authors.lastname: Altuntas
authors.forename: Leylagul
authors.initials: L
authors.lastname: Kaynar
authors.forename: Ismail
authors.initials: I
authors.lastname: Sari
authors.forename: Turkan
authors.initials: T
authors.lastname: Patiroglu
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cetin
references.citation: Cancer Treat Rep. 1987 Dec;71(12):1325-6
references.pmid: 3690552
references.citation: Vox Sang. 2004 May;86(4):263-5
references.pmid: 15144532
references.citation: Br Heart J. 1982 Apr;47(4):353-6
references.pmid: 7066120
references.citation: Haematologica. 2000 Jun;85(6):672
references.pmid: 10870133
references.citation: Bone Marrow Transplant. 2007 Aug;40(3):185-92
references.pmid: 17563736
references.citation: Br Heart J. 1978 Nov;40(11):1237-42
references.pmid: 718762
references.citation: Transfus Apher Sci. 2004 Dec;31(3):233-43
references.pmid: 15556471
references.citation: Bone Marrow Transplant. 1996 Jun;17(6):1167-9
references.pmid: 8807130
references.citation: Br Med J (Clin Res Ed). 1987 Oct 31;295(6606):1097
references.pmid: 3120894
references.citation: Bone Marrow Transplant. 1995 May;15(5):803-4
references.pmid: 7670412
references.citation: Cancer Treat Rep. 1978 Apr;62(4):573-4
references.pmid: 77729
references.citation: Annu Rev Med. 1982;33:435-43
references.pmid: 6282181
references.citation: Postgrad Med J. 1993 May;69(811):333-6
references.pmid: 8393995
references.citation: Pediatrics. 2006 Nov;118(5):2119-25
references.pmid: 17079586
references.citation: Intern Emerg Med. 2007 Oct;2(3):210-8
references.pmid: 17909702
references.citation: Vet Hum Toxicol. 2001 Dec;43(6):344-8
references.pmid: 11757993
references.citation: Allergy. 1999 Oct;54(10):1115-6
references.pmid: 10536893